Investors
The intelligence opportunity
in healthcare is no longer coming.
It is here.
HEMI is the first company to power hospitals, clinicians, and patients from a single proprietary clinical AI engine — with the IP, the deployments, and the platform architecture to lead this market.
Why HEMI. Why now.
01
Platform, not point solution
HEMI is the only company connecting hospitals, clinicians, and patients through a single proprietary AI engine. Where competitors serve one population, HEMI serves three — creating continuity of clinical intelligence no single-product company can replicate.
03
First-mover in an underserved market
The first Malaysian company to address the full healthcare journey in one platform. Southeast Asia represents a large, underpenetrated market for clinical AI — with strong government support through Malaysia Digital.
05
Partnership model — not vendor
HEMI grows solutions with clients, shaped by their clinical realities, accountable to their outcomes. This drives retention, expands deployments, and creates the feedback loop that continuously improves HEMI AI.
02
Own intelligence — not licensed
HEMI AI is built and owned by MedPlanner Sdn Bhd. No per-token licensing fees. Full control over the intelligence layer. The ability to improve in ways that licensed-model competitors cannot.
04
Medicolegal differentiation
No other clinical AI company has medicolegal protection as a founding architectural principle. HEMI Health's medicolegal suite is unique in the global market — creating a category only HEMI can serve.
06
Structural pricing advantage
Owning HEMI AI means a fundamentally different cost base. No per-token fees. Margins that competitors paying for third-party AI cannot match — enabling accessible pricing without sacrificing sustainability.
Corporate structure
Corporate Structure
MedPlanner Sdn Bhd
Malaysia
Sole owner of all HEMI AI intellectual property. Responsible for all product development, R&D, and DevOps for global clients.
Health Medical Intelligence (HEMI) Ltd
United Kingdom
Commercial headquarters. Global sales, distribution, enterprise partnerships, and investor relations.
IP & Moat
HEMI owns its intelligence.
-
Structural cost advantage — no per-token or per-seat AI licensing fees eroding margins
-
Full control — customise, update, and deepen the intelligence layer without third-party dependency
-
Defensibility — proprietary models trained on real clinical deployments are not replicable by new entrants
-
Compliance — HEMI controls its own data governance, not a third-party provider's privacy policy
INVESTOR ENQUIRY
We share material with verified investors and institutional enquiries. Our team responds within three business days.